{
  "guideline": {
    "id": "PA166104922",
    "name": "Annotation of FDA Label for flurbiprofen and CYP2C9",
    "source": "FDA",
    "version": 31,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166104922",
    "relatedChemicals": [
      {
        "id": "PA449683",
        "name": "flurbiprofen",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166311943",
      "name": "Recommendation Annotation PA166311943",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449683",
          "name": "flurbiprofen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216142,
        "html": "<p>&quot;In patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin and phenytoin), reduce the dose of flurbiprofen to avoid abnormally high plasma levels due to reduced metabolic clearance.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311929",
      "name": "Recommendation Annotation PA166311929",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449683",
          "name": "flurbiprofen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216128,
        "html": "<p>&quot;In patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin and phenytoin), reduce the dose of flurbiprofen to avoid abnormally high plasma levels due to reduced metabolic clearance.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product FLURBIPROFEN SODIUM (flurbiprofen sodium), NDA019404, Rebel Distributors Corp",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019404"
    },
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product flurbiprofen (NDA018766)",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018766"
    }
  ],
  "version": "2024-02-29-20-19"
}